CROI 2015 Program and Abstracts

Poster Listings

964 Oral Single-Dose Maraviroc Does Not Prevent Ex Vivo HIV Infection of Rectal Mucosa in Healthy HIV-1 – Negative Human Volunteers in Tissue Explants. Josep Coll 2 ; José Moltó 2 ; Jaume Boix 3 ; Laura Else 4 ; Elisabet Garcia 1 ; Roger Paredes 2 ; David Back 4 ; Bonaventura Clotet 5 ; Cecilia Cabrera 1 1 Institut de Recerca de la Sida IrsiCaixa, Institut d’Investigació en Ciències de la Salut Germans Trias i Pujol, Barcelona, Spain; 2 Fundació Lluita Contra la SIDA, Institut d’Investigació en Ciències de la Salut Germans Trias i Pujol, Barcelona, Spain; 3 Unidad de Endoscopia Digestiva. Hospital Universitario Germans Trias i Pujol, Barcelona, Spain; 4 Pharmacology Research Laboratories, Liverpool, United Kingdom; 5 Fundació Lluita Contra la SIDA-IRSICAIXA, VIC-UCC (Universitat de Vic-Universitat Central de Catalunya), Barcelona, Spain 965 CCR5 BlockadeWith Maraviroc Does Not Prevent SIVmac Oral Transmission to Macaques Egidio Brocca-Cofano 1 ; Cuiling Xu 1 ; Dongzhu Ma 1 ; Benjamin Policicchio 1 ; Kevin Raehtz 1 ; Tammy Dunsmore 1 ; George Richter-Haret 1 ; Brandon F. Keele 2 ; Ivona Pandrea 1 ; Cristian Apetrei 1 1 University of Pittsburgh, Pittsburgh, PA, US; 2 National Cancer Institute (NCI), Frederick, MD, US 966LB Correlation of In Vivo Cabotegravir Concentration and Prevention of SIV in Macaques 1 National Institutes of Health, Bethesda, MD, US; 2 Advanced Bioscience Laboratories, Inc, Rockville, MD, US; 3 Alpha StatConsult LLC, Damascus, MD, US; 4 GlaxoSmithKline, Durham, NC, US 967 MZC Gel Inhibits Ex Vivo HIV-1 and HSV-2 Infection in Human Cervical Mucosa Guillermo Villegas ; Giulia Calenda; Patrick Barnable; Keith Levendosky; Michael Cooney; José Fernández-Romero;Thomas Zydowsky; NataliaTeleshova Population Council, New York, NY, US 968 GRFT/Carrageenan Gel Inhibits SHIV-RT and HSV-2 Infection in Macaque Vaginal Mucosa Giulia Calenda 1 ; Patrick Barnable 1 ; Keith Levendosky 1 ; Kyle Kleinbeck 1 ; Agegnehu Gettie 2 ; James Blanchard 4 ; José Fernández-Romero 1 ; Barry O’Keefe 3 ;Thomas Zydowsky 1 ; Natalia Teleshova 1 1 Population Council, New York, NY, US; 2 Aaron Diamond AIDS Research Center, New York, NY, US; 3 National Cancer Institute (NCI), Fredrick, MD, US; 4 Tulane University, Covington, LA, US William R. Spreen 4 ; Anabel Lowry 1 ; Ranajit Pal 2 ;Yun LanYueh 4 ; Susan Ford 4 ; Nicola Richardson-Harman 3 ; Jim A.Turpin 1 ; FulviaVeronese 1 ; James E. Cummins 1 ABL/BIOQUAL NHPTeam 2:30 pm– 4:00 pm PrEP: Uptake 969 Sustained PrEP Use Among High-Risk African HIV Serodiscordant Couples Participating in a PrEP Demonstration Project Renee Heffron 1 ; Kenneth Ngure 2 ; Nulu Bulya Semiyaga 3 ; Josephine Odoyo 4 ; Edna Tindimwebwa 5 ; Jennifer Morton 1 ; Lara Kidoguchi 1 ; Mark A. Marzinke 6 ; Connie Celum 1 ; Jared Baeten 1 Partners Demonstration ProjectTeam 1 University of Washington, Seattle, WA, US; 2 Jomo Kenyatta University of Agriculture and Technology, Nairobi, Kenya; 3 Makerere University College of Health Sciences, Kampala, Uganda; 4 Kenya Medical Research Institute, Nairobi, Kenya; 5 Kabwohe Clinic Research Center, Kabwohe, Uganda; 6 Johns Hopkins University School of Medicine, Baltimore, MD, US 970 PrEP Engagement for HIV Prevention: Results From the iPrEx Open Label Extension (OLE) David V. Glidden 6 ; Susan P. Buchbinder 1 ; Peter L. Anderson 2 ;Vanessa McMahan 3 ; K. Rivet Amico 4 ; Albert Liu 1 ; Sybil Hosek 5 ; Megha Mehrotra 6 ; Robert M. Grant 3 iPrEx Investigators 1 San Francisco Department of Public Health, San Francisco, CA, US; 2 University of Colorado, Denver, CO, US; 3 Gladstone Institute, San Francisco, CA, US; 4 University of Michigan, Ann Arbor, MI, US; 5 John Stronger Hospital, Chicago, IL, US; 6 University of California San Francisco, San Francisco, CA, US TUESDAY, FEBRUARY 24, 2015 Session P-V3 Poster Session Poster Hall

971 Preliminary Follow-up of Injecting Drug Users Receiving Preexposure Prophylaxis Michael T. Martin 1 ; SuphakVanichseni 2 ; Pravan Suntharasamai 2 ; Udomsak Sangkum 2 ; Philip Mock 1 ; Manoj Leethochawalit 3 ; Sithisat Chiamwongpaet 3 ; Somyot Kittimunkong 4 ; Marcel Curlin 1 ; Kachit Choopanya 2 1 US Centers for Disease Control and Prevention (CDC), Nonthaburi, Thailand; 2 Bangkok Tenofovir Study Group, Bangkok, Thailand; 3 Bangkok Metropolitan Administration, Bangkok, Thailand; 4 Ministry of Public Health, Nonthaburi, Thailand 972 Recent Increases in PrEP Utilization at a Boston Community Health Center Among MenWho Have Sex With Men, 2011-2014: Transition From Research to Clinical Practice Kenneth H. Mayer 1 ; Kenneth Levine 1 ; Chris Grasso 1 ; Douglas S. Krakower 1 ; Matthew Mimiaga 2 1 Fenway Health, Boston, MA, US; 2 Harvard School of Public Health, Boston, MA, US 973 Barriers to Effective Prevention: Applying a PrEP Care Continuum to a US Cohort of Black andWhite MSM Colleen F. Kelley ; Erin M. Kahle; Aaron Siegler; Carlos del Rio;Travis Sanchez; Patrick Sullivan; Eli S. Rosenberg Emory University, Atlanta, GA, US 974 Provider Prescription of Preexposure Prophylaxis (PrEP) for HIV Infection Shikha Garg ; JohnWeiser; Linda Beer; Jacek Skarbinski US Centers for Disease Control and Prevention (CDC), Atlanta, GA, US Session P-V4 Poster Session Poster Hall 2:30 pm– 4:00 pm PrEP: Measures and Correlates of Adherence 975 Urine Assay for Tenofovir to Monitor Adherence to Tenofovir- Emtricitabine as PrEP Helen C. Koenig 1 ; KaramMounzer 1 ; GiffinW. Daughtridge 1 ; Caroline E. Sloan 1 ; Linden Lalley-Chareczko 2 ; Ganesh Moorthy 3 ; S. Caitlin Conyngham 2 ; Elizabeth Ketner 1 ; Luis J. Montaner 4 ; PabloTebas 1 1 Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, US; 2 Philadelphia FIGHT, Philadelphia, PA, US; 3 The Children’s Hospital of Philadelphia, Philadelphia, PA, US; 4 Wistar Institute, Philadelphia, PA, US 976 Comparison of Adherence Measures in a Clinical Trial of Preexposure Prophylaxis Davis C. Muganzi 1 ; Jessica Haberer 2 ;Yap Boum 1 ; Nicholas Musinguzi 1 ; Allan Ronald 4 ; Connie Celum 3 ; Jared Baeten 3 ; David R. Bangsberg 4 1 Mbarara University of Science and Technology, Kampala, Uganda; 2 Massachusetts General Hospital, Harvard Medical School, Boston, MA, US; 3 University of Washington, Seattle, WA, US; 4 University of Manitoba, Winnipeg, Canada 977 Self-Reported Recent PrEP Use Has Strong Relation to Drug Detection in iPrEx OLE Rivet Amico 1 ;Vanessa McMahan 2 ; Megha Mehrotra 2 ; Peter L. Anderson 2 ; Juan Guanira 2 ; ValdileaVeloso 2 ; Robert M. Grant 2 the iPrEx study team 1 University of Michigan, Ann Arbor, MI, US; 2 Gladstone Institute, San Fransicso, CA, US 978LB HPTN 067/ADAPT Cape Town: A Comparison of Daily and Nondaily PrEP Dosing in AfricanWomen Linda-Gail Bekker 1 ; james Hughes 2 ; Rivet Amico 4 ; Surita Roux 3 ; Craig Hendrix 5 ; Peter L. Anderson 6 ; Bonnie Dye 7 ;Vanessa Elharrar 8 ; Michael J. Stirratt 9 ; Robert Grant 10 1 Dept of Medicine and Institute of Infectious Disease and Molecular Medicine, Cape Town, South Africa; 2 HIV Prevention Trials Network, Seattle, WA, US; 3 The Desmond Tutu HIV Centre, Cape Town, South Africa; 4 University of Michigan, Ann Arbor, MI, US; 5 Johns Hopkins University, Baltimore, MD, US; 6 University of Colorado, Aurora, CO, US; 7 FHI360, Durham, NC, US; 8 PSP/ DAIDS/NIAID/NIH, Bethesda, MD, US; 9 Center for Mental Health Research on AIDS, Bethesda, MD, US; 10 University of California, San Francisco, CA, US

Poster Listings

74

CROI 2015